130 likes | 327 Views
Drug repurposing includes combination of approaches including computational biology and in vivo/in vitro studies to develop and confirm hypothesis.
E N D
Drug repositioning has seen an overwhelming growth in the last few years as drug development and pharmaceutical companies realise their drug development pipelines are gradually becoming less efficient in accomplishing the expected results. Drug repurposing includes combination of approaches including computational biology and in vivo/in vitro studies to develop and confirm hypothesis. GVK BIO is interested in strategic partnership with big pharma/biotech companies, generic drug companies and CROss to identify and develop repurposing candidates at reduced costs. In addition, we are interested in partnering with Non-profit organisations, Patient advocacy groups and Academia to develop therapeutic options for unmet medical needs through drug repurposing.
About GVK BIO: Established in 2001, GVK BIO is one of Asia’s leading life sciences service organizations. At GVK BIO, we blend science with people and technology to help accelerate drug discovery and development for more than 400 clients globally across small and large molecule platforms. Our clients include the world’s top 10 corporations in the field of Pharmaceutical, Biotechnology and Agrochemicals along with leading Academic institutions. For further information, please contact: